Skip to main content
SpringerLink
Log in

Guidelines for Stroke Prevention in Patients with Atrial Fibrillation

  • Disease Management
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Atrial fibrillation (AF) is a major independent risk factor for stroke. AF is most commonly associated with nonvalvular cardiovascular disease and is especially frequent among the elderly. The annual risk for stroke in patients with AF is approximately 5% with a wide range depending on the presence of additional risk factors. For patients who cannot successfully be converted and maintained in normal sinus rhythm (NSR), antithrombotic therapy is an effective method for preventing stroke.

The 2 drugs which are indicated for stroke prophylaxis in patients with AF are warfarin and aspirin. For primary prevention, warfarin reduces the risk of stroke approximately 68%. Aspirin therapy is less effective, resulting in a 20 to 30% risk reduction. Combination therapy with aspirin and low intensity warfarin adjusted to an International Normalised Ratio (INR) of 1.2 to 1.5 has not been shown to be superior to standard intensity warfarin with a target INR of 2.0 to 3.0.

In patients with AF and a prior history of stroke or transient ischaemic attack (TIA), the absolute risk reduction with warfarin is even greater because of the high risk of stroke in this population. In contrast, aspirin has not been shown to significantly reduce the risk of stroke in patients with AF when used for secondary prevention.

When appropriately managed, warfarin is associated with a low risk of major bleeding. In controlled trials of highly selected patients, the annual rate of intracranial haemorrhage (ICH) with warfarin was approximately 0.3%. Studies have shown that specialty anticoagulation clinics can achieve similar low rates of major bleeding. However, these results cannot be extrapolated to the general population. Factors which have been identified as predictors of bleeding include advanced age, number of medications and most importantly, the intensity of anticoagulation. INR values above 4.0 have been associated with an increased risk of major bleeding while values below 2.0 have been associated with thrombosis. Slow careful dosage titration, regular laboratory monitoring and patient education can substantially reduce the risk of complications.

In patients with AF, antithrombotic therapy has been shown to be cost effective. For high risk patients, warfarin is the most cost-effective therapy, provided the risks for bleeding are minimised. In contrast, aspirin is the most cost-effective agent for low risk patients.

Current practice guidelines for stroke prophylaxis recommend warfarin (target INR 2.5; range 2.0 to 3.0) for AF patients at high risk for stroke including those over 75 years of age or younger patients with additional risk factors. Aspirin should be reserved for low risk patients or those unable to take warfarin. Although these recommendations are strongly supported by the clinical trial evidence, studies show that many patients are not receiving appropriate antithrombotic therapy. In particular, warfarin is underutilised in high risk elderly patients. Additional studies are needed to identify barriers that prevent implementation of the clinical trial findings into clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Feinberg WM, Blackshear JL, Laupacia A. Prevalence, age distribution and gender of patients with atrial fibrillation. Arch Intern Med 1995; 155: 469–73

    Article  PubMed  CAS  Google Scholar 

  2. Hart RG, Sherman DG, Easton D, et al. Prevention of stroke in patients with nonvalvular atrial fibrillation. Neurology 1998; 51: 674–81

    Article  PubMed  CAS  Google Scholar 

  3. Halperin JL, Hart RG. Atrial fibrillation and stroke: new ideas, persisting dilemmas [editorial]. Stroke 1988; 19: 937–41

    Article  PubMed  CAS  Google Scholar 

  4. Laupacis A, Albers G, Dalen J, et al. Antithrombotic therapy in atrial fibrillation. Chest 1998; 114: 579S–89S

    Article  PubMed  CAS  Google Scholar 

  5. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991; 22: 983–8

    Article  PubMed  CAS  Google Scholar 

  6. Gresham GE, Duncan PW, Stason WP, et al. Post-stroke rehabilitation. Clinical Practice Guideline, No. 16. Rockville, MD: US Department of Health and Human Services. Public Health Service, Agency for Health Care Policy and Research. AHCPR Publication No. 95-0662, May 1995

  7. Atrial Fibrillation Follow-up Investigation of Rhythm Management — The AFFIRM Study Design. Am J Cardiol 1997; 79: 1198–201

    Article  Google Scholar 

  8. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505–11

    Article  Google Scholar 

  9. Petersen P, Godfredsen J, Boysen G, et al. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The Copenhagan AFASAK Study. Lancet 1989; 1: 175–9

    Article  PubMed  CAS  Google Scholar 

  10. Stroke Prevention in Atrial Fibrillation Investigators. The stroke prevention in atrial fibrillation study: final results. Circulation 1991; 84: 527–39

    Article  Google Scholar 

  11. Connolly SJ, Laupacis A, Gent M, et al. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol 1991; 18: 349–55

    Article  PubMed  CAS  Google Scholar 

  12. Ezekowitz MD, Bridgers SL, James KE, et al. for the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992; 327: 1406–12

    Article  PubMed  CAS  Google Scholar 

  13. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke prevention in atrial fibrillation II study. Lancet 1994; 343: 687–91

    Google Scholar 

  14. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomized clinical trial. Lancet 1996; 348: 633–8

    Article  Google Scholar 

  15. Gullov AL, Koefoed BG, Petersen P, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibirllation. Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med 1998; 158: 1513–21

    Article  PubMed  CAS  Google Scholar 

  16. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449–57

    Article  Google Scholar 

  17. Atrial Fibrillation Investigators. The efficacy of aspirin in patients with atrial fibrillation. Arch Intern Med 1997; 157: 1237–40

    Article  Google Scholar 

  18. Miller VT, Rothrock JF, Pearce LA, et al. Ischemic stroke in patients with atrial fibrillation: effect of aspirin according to stroke mechanism. Neurology 1993; 43: 32–6

    Article  PubMed  CAS  Google Scholar 

  19. Miller VT, Pearce LA, Feinberg WM, et al. Differential effect of aspirin versus warfarin on clinical stroke types in patients with atrial fibrillation. Neurology 1996; 46; 238–40

    Article  PubMed  CAS  Google Scholar 

  20. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255–62

    Google Scholar 

  21. Morocutti C, Giuseppe A, Fattapposta F, et al. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. Stroke 1997; 28: 1015–21

    Article  PubMed  CAS  Google Scholar 

  22. Diener HC, Cunha L, Forbes C, et al. European stroke prevention study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1–13

    Article  PubMed  CAS  Google Scholar 

  23. Benavente, O, Hart RG. Antiplatelet therapy to prevent stroke: risk of brain hemorrhage and efficacy in atrial fibrillation. J Neurol Sci 1997; 153: 110–2

    Article  PubMed  CAS  Google Scholar 

  24. Connolly S, for the Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation II study [letter]. Lancet 1994; 343: 1509

    PubMed  CAS  Google Scholar 

  25. Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during anti-thrombotic therapy in patients with atrial fibrillation. Arch Intern Med 1996; 156: 409–16

    Article  Google Scholar 

  26. Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation. Ann Intern Med 1993; 118: 511–20

    PubMed  CAS  Google Scholar 

  27. Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11–7

    Article  PubMed  CAS  Google Scholar 

  28. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120: 897–902

    PubMed  CAS  Google Scholar 

  29. European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulation therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995; 333: 5–10

    Article  Google Scholar 

  30. Hylek EM, Skates SJ, Sheehan MA, et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996; 335: 540–6

    Article  PubMed  CAS  Google Scholar 

  31. McCrory DC, Matchar DB, Samsa G, et al. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med 1995; 155: 277–81

    Article  PubMed  CAS  Google Scholar 

  32. Albers GW. Atrial fibrillation and stroke: three new studies, three remaining questions. Arch Intern Med 1994; 154: 1443–8

    Article  PubMed  CAS  Google Scholar 

  33. SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. JAMA 1998; 279: 1273–7

    Article  Google Scholar 

  34. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation. I: clinical features of patients at risk. Ann Intern Med 1992; 116: 1–5

    Google Scholar 

  35. American College of Physicians. Guidelines for medical treatment for stroke prevention. Ann Intern Med 1994; 121: 54–5

    Google Scholar 

  36. Stroke prevention recommendations. Rockville MD: US Department of Health and Human Services. Public Health Service, Agency for Health Care Policy and Research. AHCPR Publication No. 95-0091, September 1995

  37. ASHP therapeutic position statement on antithrombotic therapy in chronic atrial fibrillation. Am J Health Syst Pharm 1998; 55: 376–81

    Google Scholar 

  38. Gustafsson C, Asplund K, Britton M, et al. Cost effectiveness of stroke prevention in atrial fibrillation: Swedish national perspective. BMJ 1992; 305: 1457–60

    Article  PubMed  CAS  Google Scholar 

  39. Gage BF, Cardinali AB, Albers G, et al. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with atrial fibrillation. JAMA 1995; 274: 1839–45

    Article  PubMed  CAS  Google Scholar 

  40. Lightowlers S, McGuire A. Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in primary prevention of ischemic stroke. Stroke 1998; 29: 1827–32

    Article  PubMed  CAS  Google Scholar 

  41. Matchar DB, Samsa GP. Secondary and tertiary prevention of stroke: patient outcomes research team: excerpts, seventh progress report. Durham NC: Center for Health Policy Research and Education. Duke University, 1995

    Google Scholar 

  42. Gottlieb LK, Salem-Schatz S. Anticoagulation in atrial fibrillation: does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med 1994; 154: 1945–53

    Article  PubMed  CAS  Google Scholar 

  43. Leitner DA, McCart GM, Knoell K. Evaluation of anticoagulation for chronic skilled-nursing facility residents. Consult Pharm 1994; 9: 880–914

    Google Scholar 

  44. Albers GW, Yim JM, Belew KM, et al. Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals. Arch Intern Med 1996; 156: 2311–6

    Article  PubMed  CAS  Google Scholar 

  45. Stafford RS, Singer DE. National patterns of warfarin use in atrial fibrillation. Arch Intern Med 1996; 156: 2537–41

    Article  PubMed  CAS  Google Scholar 

  46. Llop R, Ferrer A, Agusti A, et al. From clinical trials to clinical practice: oral anticoagulation among patients with non-rheumatic atrial fibrillation. Eur J Clin Pharmacol 1997; 53: 1–5

    Article  PubMed  CAS  Google Scholar 

  47. Stafford RS, Singer DE. Recent national patterns of warfarin use in atrial fibrillation. Circulation 1998; 97: 1231–3

    Article  PubMed  CAS  Google Scholar 

  48. Harrison L, Johnston M, Massicotte MP, et al. Comparison of 5mg and 10mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997; 126: 133–6

    PubMed  CAS  Google Scholar 

  49. Freedman MD, Olatidoye AG. Clinically significant drug interactions with the oral anticoagulants. Drug Saf 1994; 10: 381–94

    Article  PubMed  CAS  Google Scholar 

  50. Wells PS, Holbrook AM, Crowther NR, et al. Interactions of warfarin with drugs and food. Ann Intern Med 1994; 121: 676–83

    PubMed  CAS  Google Scholar 

  51. Harris JE. Interaction of dietary factors with oral anticoagulants: review and application. J Am Diet Assoc 1995; 95: 580–4

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy Practice, School of Pharmacy, University of Kansas Medical Center, 3901 Rainbow Blvd., Kansas City, Kansas, 66160-7231, USA

    Patricia A. Howard

Authors
  1. Patricia A. Howard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patricia A. Howard.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Howard, P.A. Guidelines for Stroke Prevention in Patients with Atrial Fibrillation. Drugs 58, 997–1009 (1999). https://doi.org/10.2165/00003495-199958060-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199958060-00004

Keywords

Search

Navigation